Evidence map›Paper›PMID 41176774›Full record

ArticleCancer medicine2025

Single-Cell Transcriptomic Analysis Identifies a Novel OLR1

Xuan Yang, Xinyuan Chen, Zixin Wang, Yanfang Liu, Huiting Hu, Qingru Wu, Hailing Zhang, Yu Xiong, Xin Li, Xiaotao Cheng and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xuan YangNational key Laboratory of Immunity and Inflammation, Institute of Immunology, Naval Medical University, Shanghai, China.
Xinyuan ChenNational key Laboratory of Immunity and Inflammation, Institute of Immunology, Naval Medical University, Shanghai, China.ORCID https://orcid.org/0009-0004-5384-5442
Zixin WangNational key Laboratory of Immunity and Inflammation, Institute of Immunology, Naval Medical University, Shanghai, China.
Yanfang LiuNational key Laboratory of Immunity and Inflammation, Institute of Immunology, Naval Medical University, Shanghai, China.
Huiting HuNational key Laboratory of Immunity and Inflammation, Institute of Immunology, Naval Medical University, Shanghai, China.
Qingru WuDepartment of Neurology, Changhai Hospital, Naval Medical University, Shanghai, China.
Hailing ZhangDepartment of Neurology, Changhai Hospital, Naval Medical University, Shanghai, China.
Yu XiongAisenseBio Biomedical Technology Co., Ltd., JiangSu, China.
Xin LiAisenseBio Biomedical Technology Co., Ltd., JiangSu, China.
Xiaotao ChengAisenseBio Biomedical Technology Co., Ltd., JiangSu, China.
Xiaoyu RuanNational key Laboratory of Immunity and Inflammation, Institute of Immunology, Naval Medical University, Shanghai, China.
Yan GuNational key Laboratory of Immunity and Inflammation, Institute of Immunology, Naval Medical University, Shanghai, China.ORCID https://orcid.org/0000-0002-4481-5186

Funding

National Natural Science Foundation of China 32170918National Natural Science Foundation of China 32370974Shanghai outstanding academic leaders plan 23XD1424700Shuguang Program of Shanghai Education Development Foundation and Shanghai Municipal Education Commission 23SG32
6 · The paper itself

Abstract

backgroundPancreatic ductal adenocarcinoma (PDAC) is an exceptionally lethal malignancy, with high percents of patients presenting with liver metastases (LM). However, the mechanisms driving liver metastases remain critical bottlenecks requiring urgent exploration.

objectiveTo identify the key cellular subsets driving PDAC liver metastases, elucidate their interactions with the metastatic microenvironment, and define the underlying mechanisms of liver colonization. MATERIALS AND

methodsIntegrated single-cell transcriptomic analysis was performed using scRNA-seq data of PT and LM. The expression of signature genes within the identified cell subset was validated using clinical samples from PDAC PT and LM patients. Furthermore, ligand-receptor network analysis was conducted between the specific tumor cell subset and key immune cells.

resultsWe identified a novel liver-enriched metastatic subset (LEMS), a terminally differentiated malignant cell subpopulation characterized by metabolic reprogramming and hyperactivation of immunosuppressive pathways. We further validated the LEMS signature genes, oxidized low-density lipoprotein receptor 1 (OLR1) and solute carrier family 7 member 7 (SLC7A7), as potential diagnostic biomarkers for liver metastases. Importantly, we found that SPP1 DISCUSSION: We revealed the highly malignant features of LEMS and crosstalk between LEMS and SPP1

conclusionWe delineated LEMS as an enriched subset in LM and proposed targeting of LEMS-SPP1

Indexed as

Carcinoma, Pancreatic DuctalLiver NeoplasmsPancreatic NeoplasmsScavenger Receptors, Class AAnimalsBiomarkers, TumorGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMacrophagesMiceSingle-Cell AnalysisTranscriptomeTumor MicroenvironmentBiomarkers, TumorScavenger Receptors, Class Aimmunosuppressionliver metastasesmacrophagesmetabolic reprogrammingpancreatic ductal adenocarcinoma

Identifiers

PMID41176774
PMCPMC12579899

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.